HRP20070534T4 - Sol fosforne kiseline kao inhibitor dipeptidil peptidaze-iv - Google Patents

Sol fosforne kiseline kao inhibitor dipeptidil peptidaze-iv Download PDF

Info

Publication number
HRP20070534T4
HRP20070534T4 HR20070534T HRP20070534T HRP20070534T4 HR P20070534 T4 HRP20070534 T4 HR P20070534T4 HR 20070534 T HR20070534 T HR 20070534T HR P20070534 T HRP20070534 T HR P20070534T HR P20070534 T4 HRP20070534 T4 HR P20070534T4
Authority
HR
Croatia
Prior art keywords
crystalline
salt
weight
salt according
mohydrate
Prior art date
Application number
HR20070534T
Other languages
English (en)
Inventor
Howard Cypes Stephen
Minhua Chen Alex
R. Ferlita Russell
Hansen Karl
Lee Ivan
K. Vydra Vicky
M. Robert
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33563839&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20070534(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of HRP20070534T3 publication Critical patent/HRP20070534T3/hr
Publication of HRP20070534T4 publication Critical patent/HRP20070534T4/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Dihidrogenfosfatna sol 4-okso-4-[3-(trifluorometil)-5,6- dihidro[1,2,4]triazolo[4,3-a] pirazin-7(8H)-il]-1- (2,4,5- trifluorofenil)butan-2-amina strukturne formule II i (R)-konfiguracije gdje je kiralni centar označen s *ili njegov farmaceutski prihvatljivi hidrat. Patent sadrži još 19 patentnih zahtjeva.

Claims (20)

1. Dihidrogenfosfatna sol 4-okso-4-[3-(trifluorometil)-5,6- dihidro[1,2,4]triazolo[4,3-a] pirazin-7(8H)-il]-1- (2,4,5- trifluorofenil)butan-2-amina strukturne formule II i (R)-konfiguracije gdje je kiralni centar označen s * [image] ili njegov farmaceutski prihvatljivi hidrat.
2. Sol prema zahtjevu 1, naznačena time što je kristalični monohidrat.
3. Sol prema zahtjevu 2, naznačena time što su karakteristične vrpce apsorpcije na obrascu difrakcije X-zračenja praha dobivene na spektralnim d-razmacima od 7.42, 5.48 i 3.96 angstrema.
4. Sol prema zahtjevu 3, dalje naznačena time što su karakteristične vrpce apsorpcije na obrascu difrakcije X-zračenja praha dobivene na spektralnim d-razmacima od 6.30, 4.75 i 4.48 angstrema.
5. Sol prema zahtjevu 4, dalje naznačena time što su karakteristične vrpce apsorpcije na obrascu difrakcije X-zračenja praha dobivene na spektralnim d-razmacima od 5.85, 5.21 i 3.52 angstrema.
6. Sol prema zahtjevu 2, naznačena time što spektar C-13 CPMAS nuklearne magnetne rezonance čvrstog stanja daje signale na 169.1, 120.8 i 46.5 ppm.
7. Sol prema zahtjevu 6, dalje naznačena time što spektar C-13 CPMAS nuklearne magnetne rezonance čvrstog stanja daje signale na 159.0, 150.9 i 40.7 ppm.
8. Sol prema zahtjevu 2, naznačena time što spektar F-19 MAS nuklearne magnetne rezonance čvrstog stanja daje signale na -64.5, -114.7, -136.3 i -146.2 ppm.
9. Sol prema zahtjevu 8, dalje naznačena time što spektar F-19 MAS nuklearne magnetne rezonance čvrstog stanja daje signale na -96.5, -104.4, -106.3 i -154.5 ppm.
10. Djelatna tvar strukturne formule II, prema zahtjevu 1, koja sadrži oko 5% do oko 100% težine kristaličnog mohidrata prema zahtjevu 2.
11. Djelatna tvar prema zahtjevu 10 koja sadrži oko 10% do oko 100% težine spomenutog kristaličnog mohidrata.
12. Djelatna tvar prema zahtjevu 10 koja sadrži oko 25% do oko 100% težine spomenutog kristaličnog mohidrata.
13. Djelatna tvar prema zahtjevu 10 koja sadrži oko 50% do oko 100% težine spomenutog kristaličnog mohidrata.
14. Djelatna tvar prema zahtjevu 10 koja sadrži oko 75% do oko 100% težine spomenutog kristaličnog mohidrata.
15. Djelatna tvar prema zahtjevu 10 koja u biti u cijeloj težini sadrži spomenuti kristalični mohidrat.
16. Farmaceutska smjesa koja sadrži terapijski učinkovitu količinu soli prema zahtjevu 1 ili zahtjevu 2 zajedno s jednim ili više farmaceutski prihvatljivih nosača.
17. Postupak pripreme soli prema zahtjevu 1 koji obuhvaća korak dovođenja u doticaj jednog ekvivalenta 4-okso-4-[3- (trifluorometil)-5,6-dihidro[1,2,4]triazolo[4,3-a]pirazin-7(8H)-il]-1-(2,4,5-trifluorofenil)butan-2-amina u organskom otapalu ili vodenom organskom otapalu s oko jednim ekvivalentom fosforne kiseline pri temepraturi u rasponu oko 25-100°C.
18. Postupak prema zahtjevu 17 gdje je navedeno organsko otapalo C1-C5 linearni ili razgranati alkanol
19. Uporaba soli prema zahtjevu 1 ili zahtjevu 2 za proizvodnju lijeka za liječenje dijabetesa tipa 2.
20. Postupak pripreme kristaličnog monohidrata iz zahtjeva 2, koji obuhvaća korake: (a) kristalizacija spomenute dihidrogenfosfatne soli iz zahtjeva 1 pri 25°C iz smjese izopropanola i vode, tako da je koncentracija vode iznad 6.8 posto težine; (b) izdvajanje dobivene čvrste faze; i (c) uklanjanje otapala iz te dobivene čvrste faze. [image] [image] [image] [image] [image]
HR20070534T 2003-06-24 2007-11-21 Sol fosforne kiseline kao inhibitor dipeptidil peptidaze-iv HRP20070534T4 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48216103P 2003-06-24 2003-06-24
PCT/US2004/019683 WO2005003135A1 (en) 2003-06-24 2004-06-18 Phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor

Publications (2)

Publication Number Publication Date
HRP20070534T3 HRP20070534T3 (hr) 2007-12-31
HRP20070534T4 true HRP20070534T4 (hr) 2011-06-30

Family

ID=33563839

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20070534T HRP20070534T4 (hr) 2003-06-24 2007-11-21 Sol fosforne kiseline kao inhibitor dipeptidil peptidaze-iv

Country Status (41)

Country Link
US (1) US7326708B2 (hr)
EP (1) EP1654263B2 (hr)
JP (1) JP4463768B2 (hr)
KR (2) KR101013431B1 (hr)
CN (1) CN100430397C (hr)
AR (2) AR044705A1 (hr)
AT (1) ATE373003T1 (hr)
AU (1) AU2004253889B2 (hr)
BR (1) BRPI0411726B8 (hr)
CA (1) CA2529400C (hr)
CO (1) CO5660266A2 (hr)
CR (1) CR8117A (hr)
CY (1) CY1106936T1 (hr)
DE (1) DE602004008938T3 (hr)
DK (1) DK1654263T4 (hr)
DO (1) DOP2004000941A (hr)
EA (1) EA009042B1 (hr)
EC (1) ECSP056245A (hr)
ES (1) ES2291907T5 (hr)
GE (1) GEP20084489B (hr)
HK (1) HK1095144A1 (hr)
HR (1) HRP20070534T4 (hr)
IL (1) IL172563A (hr)
IS (1) IS2792B (hr)
JO (1) JO2625B1 (hr)
MA (1) MA27861A1 (hr)
ME (1) ME00405B (hr)
MX (1) MXPA05013931A (hr)
MY (1) MY139595A (hr)
NO (1) NO335371B1 (hr)
NZ (1) NZ544026A (hr)
PE (1) PE20050696A1 (hr)
PL (1) PL1654263T5 (hr)
PT (1) PT1654263E (hr)
RS (1) RS51873B (hr)
SI (1) SI1654263T2 (hr)
TN (1) TNSN05329A1 (hr)
TW (1) TWI347185B (hr)
UA (1) UA86026C2 (hr)
WO (1) WO2005003135A1 (hr)
ZA (1) ZA200509933B (hr)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1757606T1 (sl) * 2001-02-24 2009-10-31 Boehringer Ingelheim Pharma Ksantinski derivati za uporabo kot zdravila kot tudi postopek za njihovo pripravo
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
AU2003297219A1 (en) * 2002-12-20 2004-07-22 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US20040242566A1 (en) * 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
WO2005012346A1 (en) * 2003-07-25 2005-02-10 Conjuchem, Inc. Long lasting insulin derivatives and methods thereof
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2005016911A1 (en) * 2003-08-13 2005-02-24 Takeda Pharmaceutical Company Limited 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1662876A4 (en) * 2003-09-02 2009-01-14 Merck & Co Inc NOVEL CRYSTALLINE FORMS OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
JP2007505121A (ja) * 2003-09-08 2007-03-08 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
JP2007513058A (ja) * 2003-09-08 2007-05-24 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
EP1667524A4 (en) * 2003-09-23 2009-01-14 Merck & Co Inc NOVEL CRYSTALLINE FORM OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTASE-IV INHIBITOR
WO2005072530A1 (en) * 2004-01-16 2005-08-11 Merck & Co., Inc. Novel crystalline salts of a dipeptidyl peptidase-iv inhibitor
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN102127053A (zh) * 2004-03-15 2011-07-20 武田药品工业株式会社 二肽基肽酶抑制剂
EP1753730A1 (en) * 2004-06-04 2007-02-21 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
TW200608967A (en) 2004-07-29 2006-03-16 Sankyo Co Pharmaceutical compositions containing with diabetic agent
EP1796671A4 (en) * 2004-09-15 2009-01-21 Merck & Co Inc AMORPHOUS FORM OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP2805953B1 (en) * 2004-12-21 2016-03-09 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
EP1909776A2 (en) * 2005-07-25 2008-04-16 Merck & Co., Inc. Dodecylsulfate salt of a dipeptidyl peptidase-iv inhibitor
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
TW200738245A (en) * 2005-08-22 2007-10-16 Sankyo Co Pharmaceutical composition containing FBPase inhibitor
PL1942898T5 (pl) 2005-09-14 2014-10-31 Takeda Pharmaceuticals Co Inhibitory peptydazy dipeptydylowej do leczenia cukrzycy
ES2445180T5 (es) * 2005-09-14 2022-02-01 Takeda Pharmaceuticals Co Administración de inhibidores de dipeptidil peptidasa
CA2622642C (en) 2005-09-16 2013-12-31 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
TW200745080A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
TW200738266A (en) * 2005-09-29 2007-10-16 Sankyo Co Pharmaceutical agent containing insulin resistance improving agent
EP1942921A4 (en) * 2005-10-25 2011-03-09 Merck Sharp & Dohme COMBINATION OF A DIPEPTIDYL PEPTIDASE-4 INHIBITOR AND AN ANTI-HYPERTENING AGENT FOR THE TREATMENT OF DIABETES AND HYPERTENSION
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1999108A1 (en) * 2006-03-28 2008-12-10 Takeda Pharmaceutical Company Limited Preparation of (r)-3-aminopiperidine dihydrochloride
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
WO2007120689A2 (en) 2006-04-11 2007-10-25 Arena Pharmaceuticals, Inc. Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
KR101541791B1 (ko) 2006-05-04 2015-08-04 베링거 인겔하임 인터내셔날 게엠베하 다형태
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) * 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
EP2056673A4 (en) * 2006-08-17 2010-06-16 Wellstat Therapeutics Corp COMBINATION TREATMENT FOR METABOLISM DISEASES
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US7820666B2 (en) 2007-05-08 2010-10-26 Concert Pharmaceuticals, Inc. Tetrahydrotriazolopyrazine derivatives and uses thereof
CN101357922B (zh) * 2007-08-02 2011-05-18 山东轩竹医药科技有限公司 新的dpp-iv抑制剂
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
CN101397300B (zh) * 2007-09-04 2011-04-27 山东轩竹医药科技有限公司 二肽酶-ⅳ抑制剂衍生物
US8334385B2 (en) 2007-11-02 2012-12-18 Glenmark Generics Limited Process for the preparation of R-sitagliptin and its pharmaceutically acceptable salts thereof
US20090221595A1 (en) * 2007-11-26 2009-09-03 Nurit Perlman Crystalline form of sitagliptin
CN101903390A (zh) 2007-12-20 2010-12-01 雷迪博士实验室有限公司 制备西他列汀及其药学上可接受的盐的方法
AU2009210641A1 (en) * 2008-02-05 2009-08-13 Merck Sharp & Dohme Corp. Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-IV inhibitor
JP2011513408A (ja) * 2008-03-04 2011-04-28 メルク・シャープ・エンド・ドーム・コーポレイション メトホルミン及びジペプチジルペプチダーゼ−ｉｖ阻害剤の併用医薬組成物
TW201000485A (en) * 2008-03-25 2010-01-01 Teva Pharma Crystalline forms of sitagliptin phosphate
US20090247532A1 (en) * 2008-03-28 2009-10-01 Mae De Ltd. Crystalline polymorph of sitagliptin phosphate and its preparation
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
EP2146210A1 (en) * 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
US20090264476A1 (en) * 2008-04-18 2009-10-22 Mckelvey Craig CB-1 receptor modulator formulations
US8003672B2 (en) * 2008-04-21 2011-08-23 Merck Sharp & Dohme Corp. CB-1 receptor modulator formulations
EP2650299A1 (en) 2008-07-03 2013-10-16 Ratiopharm GmbH Crystalline salts of sitagliptin
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
MX2011001525A (es) 2008-08-15 2011-03-29 Boehringer Ingelheim Int Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
US8476437B2 (en) 2008-08-27 2013-07-02 Cadila Healthcare Limited Process for preparation of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro [1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]-l-(2,4,5-trifluorophenyl)butan-2-amine and new impurities in preparation thereof
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
RU2011113690A (ru) * 2008-09-12 2012-10-20 Кадила Фармасьютикалз Лтд. (In) Новые ингибиторы дипептидилпептидазы iv (dp-iv)
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
NZ592924A (en) 2008-12-23 2014-05-30 Boehringer Ingelheim Int Salt forms of a xanthine derivative
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
AR075204A1 (es) 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
EP2218721A1 (en) 2009-02-11 2010-08-18 LEK Pharmaceuticals d.d. Novel salts of sitagliptin
KR20160143897A (ko) 2009-02-13 2016-12-14 베링거 인겔하임 인터내셔날 게엠베하 Ｄｐｐ－４ 억제제(리나글립틴)을 임의로 다른 당뇨병 치료제와 병용하여 포함하는 당뇨병 치료 약제
PT2395983T (pt) 2009-02-13 2020-07-03 Boehringer Ingelheim Int Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dp-iv e opcionalmente um agente antidiabético adicional e suas utilizações
JP5707344B2 (ja) 2009-02-26 2015-04-30 コデクシス， インコーポレイテッド トランスアミナーゼ生体触媒
WO2010117738A2 (en) 2009-03-30 2010-10-14 Teva Pharmaceutical Industries Ltd. Solid state forms of sitagliptin salts
WO2010122578A2 (en) * 2009-04-20 2010-10-28 Msn Laboratories Limited Process for the preparation of sitagliptin and its intermediates
EP2430025A1 (en) * 2009-05-11 2012-03-21 Generics [UK] Limited Sitagliptin synthesis
WO2010131035A1 (en) * 2009-05-11 2010-11-18 Generics [Uk] Limited Novel crystalline polymorph of sitagliptin dihydrogen phosphate
CN101899047B (zh) * 2009-05-26 2016-01-20 盛世泰科生物医药技术(苏州)有限公司 作为二肽基肽酶抑制剂用于治疗或预防糖尿病的β-氨基四氢吡嗪、四氢嘧啶和四氢吡啶
CN101899048B (zh) * 2009-05-27 2013-04-17 上海恒瑞医药有限公司 (R)-7-[3-氨基-4-(2,4,5-三氟-苯基)-丁酰]-3-三氟甲基-5,6,7,8-四氢-咪唑并[1,5-a]吡嗪-1-羧酸甲酯的盐
WO2011005477A1 (en) 2009-06-22 2011-01-13 Codexis, Inc. Transaminase reactions
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
CA2771011A1 (en) * 2009-08-13 2011-02-17 Sandoz Ag Crystalline compound of 7-[(3r)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine
EP2295083A1 (de) 2009-09-15 2011-03-16 Ratiopharm GmbH Pharmazeutische Zusammensetzung mit den Wirkstoffen Metformin und Sitagliptin oder Vildagliptin
KR20210033559A (ko) 2009-11-27 2021-03-26 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
US9305057B2 (en) * 2009-12-28 2016-04-05 Oracle International Corporation Extensible indexing framework using data cartridges
KR101156587B1 (ko) * 2010-02-19 2012-06-20 한미사이언스 주식회사 시타글립틴의 제조방법 및 이에 사용되는 아민염 중간체
US20130109703A1 (en) 2010-03-18 2013-05-02 Boehringer Ingelheim International Gmbh Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
US8183373B2 (en) 2010-03-31 2012-05-22 Teva Pharmaceutical Industries Ltd. Solid state forms of sitagliptin salts
EP2556056A1 (en) 2010-04-06 2013-02-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9186392B2 (en) 2010-05-05 2015-11-17 Boehringer Ingelheim International Gmbh Combination therapy
BR112012032579B1 (pt) 2010-06-24 2021-05-11 Boehringer Ingelheim International Gmbh uso de linagliptina e composição farmacêutica compreendendo linagliptina e insulina basal de longa duração
WO2012024104A2 (en) 2010-08-16 2012-02-23 Codexis, Inc. Biocatalysts and methods for the synthesis of (1r,2r)-2-(3,4-dimethoxyphenethoxy)cyclohexanamine
WO2012025944A2 (en) 2010-08-27 2012-03-01 Usv Limited Sitagliptin, salts and polymorphs thereof
SG188548A1 (en) 2010-09-22 2013-04-30 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
CN101973997B (zh) * 2010-09-30 2012-06-06 浙江大学 一种磷酸西他列汀侧链的制备方法
AU2011327903A1 (en) * 2010-11-11 2013-05-02 Redx Pharma Plc Drug derivatives
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CN102485718B (zh) * 2010-12-03 2014-03-26 浙江海翔药业股份有限公司 西他列汀的中间体及其制备方法
WO2012076973A2 (en) 2010-12-09 2012-06-14 Aurobindo Pharma Limited Novel salts of dipeptidyl peptidase iv inhibitor
KR20130132631A (ko) 2011-03-03 2013-12-04 카딜라 핼쓰캐어 리미티드 Ｄｐｐ-ⅳ 저해제의 신규한 염
WO2012131005A1 (en) 2011-03-29 2012-10-04 Krka, Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical composition of sitagliptin
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US8524936B2 (en) 2011-05-18 2013-09-03 Milan Soukup Manufacturing process for sitagliptin from L-aspartic acid
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US8703776B2 (en) * 2011-06-15 2014-04-22 Cymabay Therapeutics, Inc. Agonists of GPR131 and uses thereof
CA2838744C (en) 2011-06-24 2020-10-13 Merck Sharp & Dohme Corp. Immobilized transaminases and process for making and using immobilized transaminase
US20150025080A1 (en) 2011-06-29 2015-01-22 Ranbaxy Laboratories Limited Solid dispersions of sitagliptin and processes for their preparation
US8895603B2 (en) * 2011-06-29 2014-11-25 Merck Sharp & Dohme Corp. Crystalline forms of a dipeptidyl peptidase-IV inhibitor
US20150051213A1 (en) 2011-06-30 2015-02-19 Suresh Babu Jayachandra Novel salts of sitagliptin
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
EA024688B1 (ru) 2011-07-27 2016-10-31 ФАРМА ДжРС, Д.О.О. Способ получения ситаглиптина и его фармацевтически приемлемых солей
WO2013032939A1 (en) 2011-08-26 2013-03-07 Metabolex, Inc. Bicyclic agonists of gpr131 and uses thereof
EA201490556A1 (ru) 2011-09-07 2014-08-29 Сановел Илач Санайи Ве Тиджарет Аноним Ширкети Составы ингибитора дпп-4
ES2487271T3 (es) 2011-10-06 2014-08-20 Sanovel Ilac Sanayi Ve Ticaret A.S. Formulaciones de dosificación sólidas inhibidoras de DPP-IV
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
CN103649090A (zh) 2011-10-14 2014-03-19 劳乐斯实验室私营有限公司 新的西他列汀盐、其制备方法及其药物组合物
US20140350023A1 (en) 2011-12-08 2014-11-27 Ranbaxy Laboratories Limited Amorphous form of sitagliptin salts
ES2421956B1 (es) 2012-03-02 2014-09-29 Moehs Ibérica S.L. Nueva forma cristalina de sulfato de sitagliptina
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN103421011B (zh) * 2012-05-25 2017-08-08 浙江海翔药业股份有限公司 一种制备磷酸西他列汀无水晶型i的方法
JP2015525793A (ja) 2012-08-08 2015-09-07 シプラ・リミテッド シタグリプチン及び中間体化合物の調製方法
CN102898387B (zh) * 2012-09-26 2015-01-07 浙江工业大学 管道化连续生产n-[(2z)-哌嗪-2-亚基]-2,2,2-三氟乙酰肼的方法
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
DK2961844T3 (da) 2013-02-28 2019-01-02 Codexis Inc Modificerede transaminasepolypeptider til industriel biokatalyse
SG11201505918TA (en) 2013-02-28 2015-09-29 Merck Sharp & Dohme Immobilized transaminases and process for making and using immobilized transaminase
US10150959B2 (en) 2013-03-15 2018-12-11 Merck Sharp & Dohme Corp. Immobilized ketoreductases and process for making and using immobilized ketoreductase
IN2013MU00916A (hr) 2013-03-20 2015-06-26 Cadila Healthcare Ltd
WO2014147641A2 (en) * 2013-03-21 2014-09-25 Laurus Labs Private Limited Sitagliptin pterostilbene phosphate salt, process for the preparation and pharmaceutical composition thereof
WO2015001568A2 (en) * 2013-07-01 2015-01-08 Laurus Labs Private Limited Sitagliptin lipoate salt, process for the preparation and pharmaceutical composition thereof
CN103387577A (zh) * 2013-07-29 2013-11-13 迪沙药业集团山东迪沙药业有限公司 西格列汀碱的不对称合成方法
CN103483218B (zh) * 2013-09-24 2015-06-03 浙江永太科技股份有限公司 一种1-(氯乙酰基)-2-(三氟乙酰基)肼的制备方法
CZ2013842A3 (cs) * 2013-11-01 2015-05-13 Zentiva, K.S. Stabilní polymorf soli (2R)-4-oxo-4-[3-(trifluorometyl)-5,6-dihydro[1,2,4]triazolo[4,3-α]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorofenyl)butan-2-aminu s kyselinou L-vinnou
PL2886544T3 (pl) 2013-12-17 2019-05-31 Sun Pharmaceutical Industries Ltd Sposób wytwarzania krystalicznego fumaranu sitagliptyny
WO2015114657A2 (en) 2014-01-21 2015-08-06 Cadila Healthcare Limited Amorphous form of sitagliptin free base
SI3102187T1 (sl) 2014-02-03 2020-08-31 Galenicum Health S.L. Stabilne farmacevtske sestave, ki vsebujejo sitagliptin v obliki tablet s takojšnjim sproščanjem
IN2014MU00651A (hr) 2014-02-25 2015-10-23 Cadila Healthcare Ltd
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
WO2015153485A1 (en) 2014-04-01 2015-10-08 The Research Foundation For The State University Of New York Electrode materials for group ii cation-based batteries
MX2016013588A (es) 2014-04-17 2017-01-26 Merck Sharp & Dohme Complejo de tanato de sitagliptina.
JP6574474B2 (ja) 2014-07-21 2019-09-11 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． キラルジペプチジルペプチダーゼ−ｉｖ阻害剤の製造方法
US10450315B2 (en) 2015-01-08 2019-10-22 Lee Pharma Limited Process for the preparation of dipeptidyl peptidase-4 (DPP-4) enzyme inhibitor
CZ27930U1 (cs) 2015-01-13 2015-03-10 Zentiva, K.S. Krystalická modifikace 3 L-vínanu (3R)-3-amino-1-[3-(trifluormethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorfenyl)butan-1-onu
CZ27898U1 (cs) 2015-01-13 2015-03-02 Zentiva, K.S. Krystalická modifikace 2 L-vínanu (3R)-3-amino-1-[3-(trifluormethyl)-6,8-dihydro-5H-[1,2,4,]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorfenyl)butan-1-onu
KR20180006881A (ko) 2015-03-09 2018-01-19 인테크린 테라퓨틱스, 아이엔씨. 비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법
WO2016162877A1 (en) * 2015-04-09 2016-10-13 Finochem Limited Harman "a process for preparing 7-[(3r)-3-amino-l-oxo-4-(2,4,5trifluorophenyl)butyi]- 5,6,7,8-tetrahydro-3-(trifluoromethyl)-l,2,4-triazolo[4,3-a]pyrazine hydrochloride monohydrate and its crystalline form"
EA201792256A1 (ru) 2015-07-24 2018-07-31 Ньюлинк Дженетикс Корпорейшн Соли и пролекарства 1-метил-d-триптофана
CN105017260B (zh) * 2015-07-30 2017-04-19 新发药业有限公司 一种西他列汀中间体三唑并吡嗪衍生物的制备方法
CN105175422B (zh) * 2015-09-18 2018-04-20 深圳市海滨制药有限公司 一种磷酸西格列汀晶体及其制备方法和用途
KR20170036288A (ko) 2015-09-24 2017-04-03 주식회사 종근당 시타글립틴의 신규염 및 이의 제조방법
JP2019517542A (ja) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング リナグリプチンおよびメトホルミンの組合せ
MX2016016260A (es) 2016-12-08 2018-06-07 Alparis Sa De Cv Nuevas formas solidas de sitagliptina.
WO2018187350A1 (en) 2017-04-03 2018-10-11 Coherus Biosciences Inc. PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
US11096890B2 (en) 2017-09-29 2021-08-24 Merck Sharp & Dohme Corp. Chewable dosage forms containing sitagliptin and metformin
CN109651373A (zh) * 2017-10-11 2019-04-19 江苏瑞科医药科技有限公司 一种西格列汀磷酸盐单水合物晶型的制备方法
KR20190060235A (ko) 2017-11-24 2019-06-03 제일약품주식회사 시타글립틴 캄실산염의 제조방법
TR201722603A2 (tr) 2017-12-28 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Metformi̇n ve si̇tagli̇pti̇n i̇çeren sicak eri̇tme ekstrüzyonu i̇le gerçekleşti̇ri̇len tablet formülasyonlari
WO2021076066A1 (en) 2019-10-14 2021-04-22 Santa Farma İlaç Sanayi̇ A.Ş. Oral formulations comprising sitagliptin hci monohydrate with improved pharmaceutical characteristics
EP3811930A1 (en) 2019-10-24 2021-04-28 Authenda Pharmaceuticals AG Oral gliptin compositions and method for preparation thereof
CN113061594B (zh) 2019-12-31 2023-11-24 弈柯莱生物科技(集团)股份有限公司 转氨酶突变体、固定化转氨酶及用于制备西他列汀的用途
CA3215858A1 (en) 2021-04-27 2022-11-03 Zhenhuan ZHENG Combination of bitter receptor agonist and gut-signaling compound
CN115671109A (zh) * 2022-11-23 2023-02-03 辽宁康辰诺信医药科技有限公司 磷酸西格列汀的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479692B1 (en) * 2001-05-02 2002-11-12 Nobex Corporation Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
EP1662876A4 (en) * 2003-09-02 2009-01-14 Merck & Co Inc NOVEL CRYSTALLINE FORMS OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
EP1667524A4 (en) * 2003-09-23 2009-01-14 Merck & Co Inc NOVEL CRYSTALLINE FORM OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTASE-IV INHIBITOR
WO2005072530A1 (en) 2004-01-16 2005-08-11 Merck & Co., Inc. Novel crystalline salts of a dipeptidyl peptidase-iv inhibitor
EP1796671A4 (en) 2004-09-15 2009-01-21 Merck & Co Inc AMORPHOUS FORM OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR

Also Published As

Publication number Publication date
KR20080022232A (ko) 2008-03-10
BRPI0411726B8 (pt) 2021-05-25
WO2005003135A1 (en) 2005-01-13
EP1654263A1 (en) 2006-05-10
DK1654263T3 (da) 2008-01-07
EP1654263B1 (en) 2007-09-12
PE20050696A1 (es) 2005-09-15
AR044705A1 (es) 2005-09-21
CA2529400C (en) 2007-10-09
KR20060026061A (ko) 2006-03-22
NO335371B1 (no) 2014-12-01
EP1654263B2 (en) 2011-02-23
IS8183A (is) 2005-12-15
CY1106936T1 (el) 2012-09-26
RS51873B (sr) 2012-02-29
DE602004008938T2 (de) 2008-08-07
CA2529400A1 (en) 2005-01-13
NO20060362L (no) 2006-03-23
IS2792B (is) 2012-08-15
AU2004253889B2 (en) 2008-04-24
ATE373003T1 (de) 2007-09-15
BRPI0411726A (pt) 2006-08-08
MEP60208A (hr) 2011-05-10
KR101016569B1 (ko) 2011-02-22
KR101013431B1 (ko) 2011-02-14
US7326708B2 (en) 2008-02-05
BRPI0411726B1 (pt) 2017-12-12
GEP20084489B (en) 2008-09-25
UA86026C2 (ru) 2009-03-25
US20050032804A1 (en) 2005-02-10
CN1832949A (zh) 2006-09-13
SI1654263T1 (sl) 2007-12-31
MXPA05013931A (es) 2006-02-24
ECSP056245A (es) 2006-10-17
TNSN05329A1 (en) 2007-07-10
RS20050947A (en) 2008-04-04
DK1654263T4 (da) 2011-06-14
DE602004008938D1 (en) 2007-10-25
ES2291907T5 (es) 2011-05-30
AU2004253889A1 (en) 2005-01-13
EA009042B1 (ru) 2007-10-26
HRP20070534T3 (hr) 2007-12-31
JP2006516268A (ja) 2006-06-29
NZ544026A (en) 2008-08-29
ME00405B (me) 2011-10-10
CN100430397C (zh) 2008-11-05
CR8117A (es) 2006-05-31
ZA200509933B (en) 2006-12-27
DE602004008938T3 (de) 2012-01-12
AR094185A2 (es) 2015-07-15
TWI347185B (en) 2011-08-21
DOP2004000941A (es) 2004-12-31
PT1654263E (pt) 2007-11-16
JP4463768B2 (ja) 2010-05-19
EA200600095A1 (ru) 2006-06-30
IL172563A (en) 2008-07-08
MY139595A (en) 2009-10-30
CO5660266A2 (es) 2006-07-31
PL1654263T5 (pl) 2011-07-29
HK1095144A1 (en) 2007-04-27
ES2291907T3 (es) 2008-03-01
TW200524610A (en) 2005-08-01
SI1654263T2 (sl) 2011-06-30
JO2625B1 (en) 2011-11-01
MA27861A1 (fr) 2006-04-03
PL1654263T3 (pl) 2008-01-31

Similar Documents

Publication Publication Date Title
HRP20070534T4 (hr) Sol fosforne kiseline kao inhibitor dipeptidil peptidaze-iv
EP2751106B1 (de) Substituierte annellierte pyrimidine und ihre verwendung
EP2324027B1 (en) New crystalline salt forms of a 5,6,7,8-tetrahydro-1,2,4- triazolo[4,3-a]pyrazine derivative
EP4098653A1 (en) Pharmaceutical use of aldehyde-based compound
WO2005020920A3 (en) Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
WO2005030127A3 (en) Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
WO2008060190A2 (fr) Ligand des récepteurs 5-ht6, composition pharmaceutique et procédé de fabrication et d'utilisation
EP3939973A1 (en) Hetero-halo inhibitors of histone deacetylase
JP2020503379A (ja) ラノステロールプロドラッグ化合物、その製造方法及び応用
EP1628980B1 (de) 6-arylmethyl-substituierte pyrazolopyrimidine
EP1525202A1 (de) Neue 2,5-disubstituierte pyrimidinderivate
US10421756B2 (en) Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
JP2022505756A (ja) Ｗｅｅ１阻害剤としてのピリミドピラゾロン類誘導体及びその使用
ES2733477T3 (es) Procedimiento eficaz para la preparación de sitagliptina a través de una preparación muy eficaz del intermedio ácido 2,4,5-trifluorofenilacético
WO2002090363A1 (en) ANHYDROUS CRYSTAL OF ss-LACTAM COMPOUND AND METHOD FOR PREPARATION THEREOF
US20140303383A1 (en) Method for purifying levo-oxiracetam
WO1999061408A1 (es) Polimorfo de gabapentina no hidratada, procedimiento para su obtención y su utilización para la obtención de gabapentina de calidad farmacéutica
US20090018336A1 (en) Racemization process of R-zopiclone
Kimmel Enantio-and Diastereoselective Additions to Nitroalkenes via N-Sulfinyl Urea Organocatalysis
CN115677710A (zh) 一种西格列汀中亚硝胺类杂质的制备方法
JPS6015633B2 (ja) 新規なジアゼピン化合物の製法
HU189660B (en) Process for the separation of enantiomers of 2,3,3a,4,5,6-hexahydro-1h-indolo/3,2,1-de/ 1,5-naphthyridine and for preparing pharmaceutical compositions containing such compounds
EA011091B1 (ru) Производные пиразолопиримидинтиона, их соли и сольваты, способы их получения и использования
JPH0470306B2 (hr)
TH102898A (th) อนุพันธ์พีร์โรโล[3,4-c]ไพราโซลซึ่งมีฤทธิ์เป็นสารยับยั้งไคเนส, กระบวนการสำหรับการเตรียมสารดังกล่าวและองค์ประกอบทางเภสัชกรรมที่ประกอบรวมด้วยสารดังกล่าว